Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $891000.0.

  • Century Therapeutics' Share-based Compensation fell 7314.65% to $891000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 3966.89%. This contributed to the annual value of $12.7 million for FY2024, which is 1322.66% down from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Share-based Compensation is $891000.0, which was down 7314.65% from $2.2 million recorded in Q2 2025.
  • Century Therapeutics' Share-based Compensation's 5-year high stood at $4.0 million during Q3 2023, with a 5-year trough of $891000.0 in Q3 2025.
  • Moreover, its 4-year median value for Share-based Compensation was $2.8 million (2022), whereas its average is $2.9 million.
  • In the last 5 years, Century Therapeutics' Share-based Compensation surged by 5953.78% in 2023 and then crashed by 7314.65% in 2025.
  • Over the past 4 years, Century Therapeutics' Share-based Compensation (Quarter) stood at $2.7 million in 2022, then soared by 30.38% to $3.6 million in 2023, then fell by 25.32% to $2.7 million in 2024, then crashed by 66.5% to $891000.0 in 2025.
  • Its Share-based Compensation was $891000.0 in Q3 2025, compared to $2.2 million in Q2 2025 and $2.4 million in Q1 2025.